Candel Therapeutics Inc (NASDAQ:CADL),, a clinical-stage biopharmaceutical company, will present new data from its phase 3 trial of aglatimagene besadenovec (CAN-2409) in intermediate- to high-risk localized prostate cancer at the American Urological Association 2026 Annual Meeting.
The plenary session, titled “Practice-changing, Paradigm-shifting Clinical Trials in Urology,” will be held on May 15 in Washington, D.C., highlighting extended follow-up results on patient outcomes with CAN-2409 plus standard radiation therapy.